The latter demonstrated that the SVd triplet regimen was associated with improved PFS in patients harboring amp(1q), though with borderline significance (HR: 0.63, 95% CI: 0.34–1.17, p = 0.07), consistent with findings observed in the overall study population.
Although the limited number of cases with combined +1q and other cytogenetic abnormalities limited sample sizes, a clear trend emerged: the presence of +1q in conjunction with high‐risk abnormalities consistently correlated with worse PFS and OS outcomes.
Conversely, ISS Stage II ( p = 0.1), two prior lines of therapy ( p = 0.056), and impaired renal function (CrCl < 60 mL/min) ( p = 0.08), though suggestive of worse outcomes, did not reach statistical significance.